Xilio Therapeutics (XLO) AI Stock Analysis

• Market Cap: $38.62M
• Dividend Yield: N/A
• Average Volume (3M): 1.36M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.69
• Revenue Growth: N/A
• EPS Growth: 53.92%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 51,773,716
• 10 Day Avg. Volume: 263,316
• 30 Day Avg. Volume: 1,363,685
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 6.45
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.50
• Price Target Upside: 500.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Xilio Therapeutics faces challenges in profitability and valuation, impacting financial performance. However, recent strategic partnerships and investments provide a strong foundation for future growth. Technical indicators suggest a cautious market outlook, but corporate events bolster long-term prospects.

Positive Factors

Clinical Trial Results

The vilastobart combination therapy also demonstrates a better safety and tolerability profile compared to competing therapies.

Collaboration

The collaboration agreement with AbbVie further validates Xilio's capabilities and notably extends the cash runway.

Pipeline Development

Xilio plans to nominate multiple development candidates for its ATACR and SEECR platforms over the next few years, indicating a strong pipeline.

Negative Factors

Clinical Trial Challenges

XTX-202 was being tested in a Phase I/II trial with expansion cohorts in melanoma/RCC. However, the monotherapy program was ultimately discontinued due to modest efficacy.

Financial Outlook

Current cash supports operations through 2Q25, providing financial stability for continued development.

Xilio Therapeutics Business Overview & Revenue Model

Company Description

Xilio Therapeutics (XLO) is a biotechnology company focused on developing tumor-selective immuno-oncology therapies. It operates within the healthcare and biotechnology sectors, with a core emphasis on engineering therapies that localize their activity within tumors to minimize systemic toxicity. The company's proprietary technology platform is designed to enhance the therapeutic index of its drugs, aiming to offer more effective and safer cancer treatments.

How the Company Makes Money

Xilio Therapeutics makes money primarily through the development and potential commercialization of its proprietary cancer therapies. The company invests in research and development to create innovative tumor-selective treatments, which it aims to bring to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams may include upfront payments, milestone payments, and royalties from licensing agreements, as well as eventual product sales pending successful clinical trials and regulatory approvals. Additionally, partnerships with other biotech or pharmaceutical firms can provide funding and resources to advance the development of its therapeutic candidates.

Xilio Therapeutics Financial Statement Overview

Summary

Xilio Therapeutics shows initial revenue generation but faces challenges with profitability and cash flow. Despite moderate financial stability, high liabilities and negative equity trends pose risks. Improving operational efficiency and cash flow is crucial.

Income Statement

Xilio Therapeutics shows a recent improvement in revenue, achieving $6.34M in 2024, up from zero in previous years. However, the company continues to operate at a loss, with negative EBIT and EBITDA margins and no net income, indicating a challenging profitability scenario.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio due to its high equity levels, but its equity has been decreasing over time. The equity ratio is moderate, showing some financial stability. High liabilities relative to assets pose a risk.

Cash Flow

Free cash flow remains negative, but there was a significant cash inflow from financing activities in 2024. Operating cash flow to net income is not applicable due to the absence of net income, indicating cash flow challenges despite recent revenue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.34M	0.00	0.00	0.00	0.00
	Gross Profit
6.34M	-1.90M	-1.85M	-1.50M	-1.06M
	EBIT
-60.58M	-79.13M	-89.15M	-75.04M	-54.56M
	EBITDA
-58.00M	-73.80M	-85.58M	-73.70M	-53.50M
	Net Income Common Stockholders
-58.24M	-76.40M	-87.30M	-74.30M	-55.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
55.29M	44.70M	120.39M	198.05M	19.24M
	Total Assets
71.08M	60.93M	139.16M	218.06M	36.32M
	Total Debt
8.14M	11.46M	19.94M	20.54M	21.22M
	Net Debt
-47.15M	-33.25M	-100.45M	-177.52M	1.98M
	Total Liabilities
53.48M	24.10M	33.52M	32.63M	119.60M
	Stockholders Equity
17.60M	36.83M	105.65M	185.43M	-83.29M
Cash Flow		Free Cash Flow
-18.41M	-69.11K	-77.59M	-81.85M	-38.28M
	Operating Cash Flow
-18.38M	-68.62M	-75.72M	-80.75M	-36.09M
	Investing Cash Flow
-36.00K	-486.00K	-1.87M	-1.10M	-2.19M
	Financing Cash Flow
29.20M	-6.55M	-69.00K	260.67M	10.03M

Xilio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.87, and below the 200-day MA of 0.92, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XLO.

Xilio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLO	54 Neutral	$38.62M	―	-214.02%	―	―	53.92%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
FHTX	48 Neutral	$195.76M	―	322.49%	―	-33.83%	27.89%
IMTX	45 Neutral	$552.62M	57.44	3.73%	―	188.64%	―
KPTI	40 Underperform	$35.01M	―	41.08%	―	-0.55%	49.85%
ALXO	38 Underperform	$34.97M	―	-88.91%	―	―	30.37%
TNGX	35 Underperform	$158.92M	―	-57.58%	―	15.18%	-9.47%

Xilio Therapeutics Corporate Events

Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion

On February 10, 2025, Xilio Therapeutics announced a collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies. The agreement includes an upfront payment of $52 million and potential contingent payments up to $2.1 billion. AbbVie will leverage its oncology expertise alongside Xilio’s proprietary technology to advance masked T cell engagers and other immunotherapies. This collaboration positions Xilio to accelerate its technology’s expansion into next-generation therapies, potentially enhancing its market presence and providing significant financial benefits.

Xilio Therapeutics Advances with Phase 2 Trial Data

On January 21, 2025, Xilio Therapeutics announced initial data from a Phase 2 clinical trial evaluating vilastobart (XTX101) combined with atezolizumab for advanced solid tumors, which will be presented at the 2025 ASCO Gastrointestinal Cancer Symposium. This development marks a significant step in Xilio’s clinical programs, highlighting its potential impact on the oncology landscape and providing insights into their collaboration with Roche and strategic goals in advancing cancer treatment options.